Roche highlights fenebrutinib’s impact on chronic MS lesions ahead of FDA decision
Roche presented new phase 3 data for fenebrutinib at the MS Toronto 2026 conference, highlighting its potential to reduce chronic active lesions and brain volume loss in multiple sclerosis. The company aims for FDA approval next year, with analysts debating its market position against existing therapies.